DiscGenics, Inc.

Jul 16, 2024

DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease

Aug 25, 2020

DiscGenics Raises $50 Million in Series C Funding

Sep 24, 2019

DiscGenics Announces Publication of Preclinical Data for Disc Degeneration Treatment in The Spine Journal

Sep 16, 2019

DiscGenics' U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark

Aug 26, 2019

DiscGenics Receives FDA Fast Track Designation for Cell Therapy for Disc Degeneration

Jul 10, 2019

First Utahns treated in nationwide FDA-allowed clinical study of locally developed cell therapy for chronic low back pain

Dec 11, 2018

DiscGenics Receives Approval from Japanese Pharmaceuticals and Medical Devices Agency to Begin Clinical Evaluation of Non-Surgical Degenerative Disc Disease Treatment in Japan

Sep 26, 2018

DiscGenics to Present at 2018 Cell & Gene Meeting on the Mesa

Apr 26, 2018

DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease

Mar 22, 2018

DiscGenics Presents Promising Preclinical Study Results at ORS 2018

Oct 03, 2017

DiscGenics Receives FDA Allowance of IND to Commence Clinical Study of Its Degenerative Disc Disease Therapy

Sep 26, 2017

DiscGenics Raises $14 Million in Series B Financing